Core Insights - LIXTE Biotechnology Holdings, Inc. has acquired Liora Technologies Europe Ltd., marking its entry into the radiotherapy segment of cancer care [1][3] - The acquisition includes Liora's LiGHT System, which offers significant advantages in proton therapy for treating tumors [2][3] - The LiGHT System is expected to set a new standard in cancer treatment, providing high-precision therapy that is scalable and clinically versatile [3] Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, with a lead compound, LB-100, that has shown promise in clinical trials [4][5] - The company aims to enhance existing cancer treatments through its innovative approach in cancer biology, specifically in activation lethality [5] Technology and Development - The LiGHT System, installed at STFC's Daresbury Laboratory, will serve as a center of excellence for proton therapy treatment [2] - The technology is designed to reduce installation costs and treatment sessions while increasing patient capacity at treatment centers [3]